Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas.

Publication Type:

Journal Article

Source:

Clinical cancer research : an official journal of the American Association for Cancer Research, Volume 11, Issue 13, p.4857-66 (2005)

Keywords:

Acyltransferases, Alanine Transaminase, Animals, Antibodies, Monoclonal, Antibodies, Monoclonal, Murine-Derived, Antigens, CD20, Antineoplastic Combined Chemotherapy Protocols, APOPTOSIS, Aspartate Aminotransferases, Caspases, Cell Line, Tumor, Dose-Response Relationship, Drug, Enzyme Inhibitors, Humans, Hydrocarbons, Halogenated, Injections, Intraperitoneal, Lymphoma, Non-Hodgkin, MICE, Mice, Nude, Mice, SCID, Specific Pathogen-Free Organisms, Survival Analysis, Thymidine, Time Factors, Treatment Outcome, Triazines, Tritium, Xenograft Model Antitumor Assays

Abstract:

Lysophosphatidic acid acyltransferase-beta (LPAAT-beta) is a transmembrane enzyme critical for the biosynthesis of phosphoglycerides whose product, phosphatidic acid, plays a key role in raf and AKT/mTor-mediated signal transduction.